Skip to content
Home / News |

N4 Pharma Shares Plunged 28.6% on a Broker Offer To Raise £1M

The N4 Pharma PLC (LON: N4P) share price plunged 28.6% after announcing a new broker offer to raise up to £1.0 million. The offer’s initial target is to raise £0.25 million, but the amount could be extended to the upper figure if the issue is oversubscribed.


eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.


Investors reacted negatively to the news given that the new shares were priced at 2 pence each, representing a significant premium to Thrusday’s closing price of 2.80p. The company’s shares had traded at a high of 3.64p in mid-October, demonstrating its potential to trade at higher prices. 

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG
5.0
View Offers
Empfohlener Broker Multi Asset Platform
Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro
5.0
Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

The decline in N4 Pharma’s share price reflected the significant discount offered to the shareholders participating in the offer. 

N4 Pharma’s last significant announcement before today’s news was at the beginning of November when it gave an update regarding the patents it had filed in March 2020. The company has filed patents related to its proprietary Nuvec® technology.

The specialist pharmaceutical company noted that Nuvec® could manufacture viral vectors and make viral vectors more efficient in applications such as ex-vivo gene therapy treatments. Therefore, it filed for a Patent Cooperation Treaty (PCT) application. 

Moreover, the company decided to update its patent application with a focus on its claims regarding using the specific spiky properties of Nuvec™ to load and transfect viral vectors, especially adenoviral and lentiviral vectors.

The company has filed for patents in the USA, India, Japan, Europe (including the UK), and Canada. The firm also plans to file for patents in Australia and China. 

So, will N4 Pharma shares recover from today’s decline? Only time can tell, but any progress the company reports could trigger a rally higher. 

*This is not investment advice. 

N4 Pharma share price.

The  N4 Pharma share price plunged 28.57% to trade at 2.00p, falling from Thursday’s closing price of 2.80p.

Simon Mugo
Contributor

Simon ist Autor und Analyst für den Bereich Finanzwesen und blickt auf über sechs Jahre professionelle Erfahrung als Trader zurück. Er absolvierte einen Bachelor in Mathematik und Informatik und hat eine Leidenschaft für die Finanzmärkte. Simon handelt FX, Rohstoffe und Aktien. Er konzentriert sich auf Price Action Trading.